Since its inception in 2016, Nanjing Remain Bio Technology Co., Ltd. has honed in on the realm of whole blood and capillary blood precision testing. Its hallmark technology, direct chemiluminescence detection applied to whole blood and capillary blood, facilitates clinical-grade testing with merely a single drop of fingertip blood. Lately, the company has successfully closed its Series C financing round, spearheaded by Hanyuan Jiantou Fund, with additional participation from the Huangshan Zhanxin Fund, managed by Anfulan Capital. Presently, the company is witnessing swift growth in sales revenue, boasting a cumulative installed base of over 1,000 units, including more than 500 units in tertiary hospitals. Its business footprint spans more than twenty countries and regions, with an embryonic international business ecosystem taking shape. Moreover, the company is vigorously venturing into mass health management domains such as precision anti-aging, partnering with the Yangtze River Delta Advanced Medical Technology Innovation Center on research endeavors. It also envisions harnessing AI technology to offer personalized precision anti-aging advice by integrating traffic from Huangshan's tourism and wellness landscapes. Looking ahead, the company intends to deploy the raised funds to expedite the construction of its Huangshan production hub, intensify its overseas expansion, advance AI-driven health management services, and aspire to emerge as a new-generation precision health management listed entity propelled by both B2B and B2C business models. The investors are poised to provide holistic empowerment and steadfast support.